Divalproex-ER pharmacokinetics in older children and adolescents

Pediatric Neurology

Volumn 30, Issue 5, 2004, Pages 330-337

  Dutta, Sandeep ^a,i   Zhang, Yiming ^a   Conway, Jeannine M ^b   Sallee, Floyd R ^c   Biton, Victor ^d   Reed, Michael D ^e   Kearns, Gregory L ^f,g,h  

^a ABBOTT LABORATORIES   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d Arkansas Epilepsy Program   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^g CHILDREN S MERCY HOSPITAL   (United States)

^h EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

ⁱ Bldg AP13A ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VALPROATE SEMISODIUM;

ADOLESCENCE; ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; MALE; OPEN STUDY; PEDIATRICS; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; STANDARDIZATION; TABLET; TIME;

ADOLESCENT; ADULT; AREA UNDER CURVE; CHILD; CONFIDENCE INTERVALS; DELAYED-ACTION PREPARATIONS; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; VALPROIC ACID;

EID: 2542455648     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2003.12.006     Document Type: Article

References (15)

1. Hoppener R.J., Kuyer A., Meijer J.W., Hulsman J. Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects. Epilepsia. 21:1980;341-350
2. Cloyd J.C., Fischer J.H., Kriel R.L., Kraus D.M. Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin Pharmacol Therap. 53:1993;22-29
3. Cloyd J.C., Kriel R.L., Jones-Saete C.M., Ong B.Y., Jancik J.T., Remmel R.P. Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference. J Pediatr. 120:1992;634-638
4. Depakote ER Tablets Product Information. Divalproex Sodium Extended-Release Tablets, Abbott Laboratories, Inc., North Chicago, IL, January 2003
5. Beal S, Sheiner L. NONMEM, Version V 1.1, NONMEM Project Group, University of California, San Francisco, 1998
6. MacKichan JJ. Influence of protein binding and use of unbound (free) drug concentrations. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics, 3rd ed. Vancouver, Canada: Applied Therapeutics, Inc., 1992:5-1-5-48
7. Cavanaugh J.H., Granneman R., Lamm J., Linnen P., Chun A.H.C. Effect of food on the bioavailability of a controlled-release formulation of Depakote under multiple-dose conditions. Epilepsia. 38:1997;54
8. Cloyd J.C., Dutta S., Cao G., Walch J.K., Collins S.D., Granneman G.R. The Depacon Study Group. Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. Epilepsy Res. 53:2003;19-27
9. Levy R.H., Shen D.D., Abbott F.S., Riggs W., Hachad H. Valproic acid Chemistry, biotransformation, and pharmacokinetics. Levy R.H., Mattson R.H., Meldrum B.S., Perucca E. Antiepileptic drugs. 5th ed :2002;780-800 Raven Press, New York
10. Dutta S., Zhang Y., Selness D.S., Lee L.L., Williams L.A., Sommerville K.W. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res. 49:2002;1-10
11. Sommerville K.W., Dutta S., Biton V., Zhang Y., Cloyd J.C., Uthman B. Bioavailability of a divalproex extended-release formulation versus the conventional divalproex formulation in adult patients receiving enzyme-inducing antiepileptic drugs. Clin Drug Investig. 23:2003;661-670
12. Chiba K., Suganuma T., Ishizaki T., et al. Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug treatment. J Pediatr. 106:1985;653-658
13. Bourgeois B.F.D. Valproic acid Clinical efficacy and use in epilepsy. Levy R.H., Mattson R.H., Meldrum B.S., Perucca E. Antiepileptic drugs. 5th ed :2002;808-817 Raven Press, New York
14. Kodama Y., Kodama H., Kuranari M., Tsutsumi K., Ono S., Fujimura A. No effect of gender or age on binding characteristics of valproic acid to serum proteins in pediatric patients with epilepsy. J Clin Pharmacol. 39:1999;1070-1076
15. Scheyer R.D., Cramer J.A., Toftness B.R., Hochholzer J.M., Mattson R.H. In vivo determination of valproate binding constants during sole and multi-drug therapy. Therap Drug Monitor. 12:1990;117-123